Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (23787)	2/23/1999 1:39:00 PM
From: Jules	Respond to of 50167

NEWS!!! Techne Acquires Cistron Biotechnology's Research Reagents Business and Exclusive Sublicense to Certain Interleukin 1 Beta Patents for the Research Market Jump to first matched term MINNEAPOLIS, Feb. 23 /PRNewswire/ -- Techne Corporation (Nasdaq: TECH) and Cistron Biotechnology, Inc. (OTC Bulletin Board: CIST) announced today that through TECHNE's subsidiary, Research and Diagnostics Systems, Inc. (R&D Systems), TECHNE has purchased from Cistron its research reagents business and exclusive research market rights to Interleukin 1 beta (IL-1B) antibody and immunoassay patents. Cistron will retain diagnostic and therapeutic marketing rights on the IL-1B patents. The effective date of the acquisition is April 1, 1999. R&D Systems paid $750,000 cash for Cistron's research reagents business and IL-1B research market patent rights. In addition, royalties will be paid on the net sales of IL-1B proteins, antibodies and immunoassays by TECHNE and its subsidiaries for the life of the patents. Cistron's research reagent sales for their fiscal year ended June 30,1998 were approximately $550,000. Thomas E. Oland, President of TECHNE said, "We have had a working relationship with Cistron for a number of years and we were very pleased that they came to us when they decided to withdraw from the research reagents market place. We believe we are the leaders in the cytokine research reagents market and that we will be able to maximize Cistron's royalty stream on sales of IL-1B." Bruce C. Galton, Chairman and CEO of Cistron said, "Cistron is concentrating on the research and development of the therapeutic and diagnostic applications of our technologies rather than continue the production and sale of research reagents. R&D Systems was a natural choice to work with for the research product market due to their scientific strength and marketing expertise." Cistron's primary product area is immune response regulators known as lymphokines. The company is developing therapeutic and diagnostic applications of its technology for cancer, arthritis and other auto immune diseases. TECHNE Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe Ltd. of Abingdon England. R&D Systems is a specialty manufacturer of biological products and R&D Systems Europe is a distributor of biotechnology products. ------ Previous

To: Skywatcher who wrote (23787)	2/23/1999 1:55:00 PM
From: IQBAL LATIF	Respond to of 50167

Chris-- OT When history is in making a constant taveler like me end up ih these situations very often, it was in Dorchester last year on Executive floor when Madame Albright was trying to bring Mr Arafat and Nathanyahu together and on our executive floor lounge walked in Mr Nathanyahu with his wife, so where ever peace and efforts are in progress small footnotes like us remind them of their obligation to human kind at large.. One can be a great trader but I woulod like myself to be a great human being too, a person who cares for what is happening around him.. Understanding events is most important issue for true interpretations of markets moves. Economy in global terms is no more a single country phenomenon it is about global integration and someone like me taking my cue from global events as some of my numbersresult from global events I think it all helps to serve tyhe market calls with little more precision.. With all my incomprehensiblity I know one thing when I write I 'value add', that is what matters to me the most, I don't therefore get bogged down with Clinton impeachment I know it there is going to be none so for me I have that advantage of political understanding which helps ly trades on long side of the market as like others I don't have to waste my precious time on vices of impeachment or impact on markets the noise always dies away, and I say very often ' strong economy produces strong bottom lines that is what it boils down too. .. Info is available for me it is defining and interpreting events that makes a better trader, no one is a better trader than these politicians I learn the art of political economy from these guys and so far watching them is just great.. This thread is about studying human life, the combination of greed and callousness and its fortune making ability. For me all this adds up in becoming a better trader. I feel just great to be a part of experiment on SI to host this thread from 7000 miles away, it is me who gets the pit action minutes from Chicago and it this advancement of mankind I am over-awed with..